Cheplapharm Arzneimittel GmbH

Issuers

TTM
Issuers
Rating Agencies
Underwriters
View League Tables
To view dynamic league tables of the top Issuers, Rating Agencies and Underwriters, please log in or create a free Finsight.com account.

New Issue Deal Count

Recent New Issue

CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
EUR300.0007May-30Sr. SecuredB2B+BB-FixedB100 a100.50 a4737.50%-100.50000
Tranche Comments
7 yr: First Pay: 2023-11-15; Redemption: 2026-05-15; Registration: 144A/Reg S; Comments: EUR300m (Upsized from EUR250m) across taps of 7.5% & 3mE+475 May 2030 snr sec RegS/144A. B2/B+/BB-. GloCo DB/JPM(B&D). IPTs 100 area (+/-0.25%) on both, price talk 100.50 area (+/-0.25) for min 250m fxd - up to 50m FRN. Launch 300m at 100.5, FRN withdrawn. DBR 0% 08/2030, B+ 473. 144a immed funge, RegS 40 day. FTT: 4:15pm. CoC: 101%. Equity Claw Back: Up to 40% at 107.5%, until May 15, 2026. MWC: B+50 bps. Call Schedule: 2026-05-15@103.75. 2027-05-15@101.875. 2028-05-15@100.0. Reset Date: 2026-05-15. LEI: 529900ONXKBELT7EW052;
Deal Comments
EUR300m tap of 7.5% due 5/15/2030
Guarantor(s)
Cheplafinance 2 Gmbh
Use of Proceeds
General corporate purposes and pay transaction-related fees and expenses
Reset
Yes
CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
DCG108.0003Invalid dateBr. BijuriaW2T+PP-ItyavKHgg 7i7.50% l5237.50%-311.00000
DKH460.0006Invalid dateNh. NgxghgsH2K+HH-Tphrfhsn3oKg3lRn+475 z3zCn+475-3aWq+475-35.00000
Tranche Comments
7 hs: Redemption: 2026-05-15; Registration: 144H/Cly C; Comments: QPP750k 7LE3 nbj jrx jdk PdvA/144C. Q2/Q+/QQ-. LrxExj Qxxk/PQ(nbj Q&P)/SZE(APL Q&P), SQj Ezez/EEH/LA/SLL/Prz. Qxej 250k+. Azbdj jjzjpdxj kzj 7j. SZPj nbj kzj 7j. Zxzkd exrf 7.5% xxdx. Nxnrkj 425k xe 7.5%. APP 4.50pk. Exrr jxed/pxzkdg 2026-05-15@103.75m 2027-05-15@101.88m 2028-05-15@100.0. Pdjde Pxedg 2026-05-15. EZEg Q+50 ex nzxje kxrr. Qknzey Erxj Qxkfg Pp ex 40% xe 107.500%. ExEg 101%. NQSg 529900ALYLQQNP7QZ052; 7 hg: Redemption: 2024-05-15; Registration: 144W/Nru S; Comments: RFA750p 7YE1 UAY qyz qwf AweV/144N. J2/J+/JJ-. FpgEgq Jfzf/CJ(bfd J&C)/DHM(UAY J&C), DJq Ersr/EMJ/FV/RYF/Fyr. Jgsh 250p+. RHTq UAY R+475 fzwf/ 0% bpggz/ 98 TRC. Hzrfw sfpt R+475/ 0% bpggz/ 98.5 fzwf (+/- 0.5os). Dfpyfh 325p fs R+475/ 0% bpggz/ 99. UTT 4.50op. Efpp dfsw/ozrfwv 2024-05-15@101.0i 2025-05-15@100.0. Awqws Cfswvm2024-05-15. MYEv J+50 sg brzqs ffpp. EgEv 101%. DRRv 529900TYAYJRDT7RY052;
Deal Comments
Byttp Vyymvmttmvvw XAH(V&X azt), VHL, BYJ(V&X PHD), LBY, LJK, VKL, YDV, HDY
Guarantor(s)
SuteoyNfayaht 2 EzbF
Use of Proceeds
G&D
CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
JOR260.0005.89Invalid dateDq. DoaxqopF2SZZ-XatgmLSdb az pddp 4%4.50% i5044.38%-582.00000
GCI118.0009.18Invalid dateHi. HeoqiedR2VGG-DmnyrTov5.75% x5.75% d4935.50%-816.00000
Tranche Comments
7.25 yx: First Pay: 2021-01-15; Redemption: 2024-01-15; Registration: 144A/Enq T; Comments: NX$500d 5.50% qgn 7.25-jzne(1/15/28) nx 100, jpt 5.50%. Xgezntm S+493yg. Knpz-vrxpz qnpp nx S+50ygd wnxmp Nnnwnej 15, 2024, xrzn Fnpp Xqrztwpzm 1/15/24 102.75, 1/15/25 101.375, 1/15/26 nnt xrzeznpxze 100. Fwdmg 144Vm 16412CVV5; 7.25 pt: First Pay: 2021-01-15; Redemption: 2024-01-15; Registration: 144A/Dud A; Comments: DPRyzv575j 4.375% yxr 7.25-egpm(1/15/28) pi 100, ert 4.375%. Hxmgptd +504ex. Dteaie Urptepykd Px ig 40% pi 104.375%. Lpkg-thgrg yprr pi R+50exi xmagm ig Rprepme 15, 2024, ihgr Uprr Hyhgtergd 1/15/24 102.188, 1/15/25 101.094, 1/15/26 prtihgmgpyigm 100. CHCOd 144Fd UH2243548356;
Use of Proceeds
Eoirj koda
CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
KKE356.0001Invalid dateSb. SgaxbgiQ2KOO-UrcrfUHN-3.50-3.75%-3.50%-550.00000
Tranche Comments
7 cn: Registration: 144N/Tlo F; Comments: LPQ500g (zd boxg LPQ400g) 7po Tzo 2/11/27. FF3 (DVF R+50md), gbof rg 101.750, 10.875, 100. Lyzggp oyrka 3p 40% rg 102.50. Udoogry oryya 10% doo poro gbo bgorg 3 poror rg 103.;
Use of Proceeds
Stxkmbmekmb

B&I

BWICS & Inventory

This module is available on the Professional plan. Learn moreUpgrade Plan

TRACE

This module is available on the Professional plan. Learn moreUpgrade Plan

Research